Q2 FY2026 EarningsQ2 FY26 results beat consensus on earnings while remaining pre-revenue: Net Loss of $23.5M was narrower than the $27.7M expected, resulting in a GAAP EPS of -$0.46 vs. -$0.65 consensus. The earnings beat was driven by higher-than-expected interest income of $4.8M, offsetting increased R&D and G&A spend. With cash reserves of $819.9M following a May follow-on offering, the company has extended its runway into 2030, supporting multiple Phase 3 readouts for lead candidate VDPHL01.
Financial report interval: 2026.03.30 - 2026.06.30
Overview: VeraDermics(MANE) the EBIT is -29.55 M (--%), Beat estimate;the EPS is -0.58 (--%), Beat estimate.
Actual
YoY
Estimate
YoY
Vs estimate
YoY
Revenue
TBA--
0.00B--
----
EBITExceed expectations
-0.03B--
-0.03B--
+0.00B--%
EPSExceed expectations
-0.58--
-0.654--
+0.0740--%
Revenue
ActualEstimateUnit: USD
qf
EBIT
ActualEstimateUnit: USD
qf
Net income
ActualEstimateUnit: USD
qf
EPS
ActualEstimateUnit: USD
qf